{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T16:57:39Z","timestamp":1769360259622,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T00:00:00Z","timestamp":1481587200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1038\/tpj.2016.89","type":"journal-article","created":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T11:04:58Z","timestamp":1481627098000},"page":"173-179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A polymorphism in the OPRM1 3\u2032-untranslated region is associated with methadone efficacy in treating opioid dependence"],"prefix":"10.1038","volume":"18","author":[{"given":"R C","family":"Crist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G A","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E C","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Degenhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N G","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G W","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A J","family":"Saxon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W H","family":"Berrettini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,13]]},"reference":[{"key":"BFtpj201689_CR1","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/add.12551","volume":"109","author":"L Degenhardt","year":"2014","unstructured":"Degenhardt L, Charlson F, Mathers B, Hall WD, Flaxman AD, Johns N et al. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction 2014; 109: 1320\u20131333.","journal-title":"Addiction"},{"key":"BFtpj201689_CR2","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1526-4637.2011.01075.x","volume":"12","author":"HG Birnbaum","year":"2011","unstructured":"Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL . Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med 2011; 12: 657\u2013667.","journal-title":"Pain Med"},{"key":"BFtpj201689_CR3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1749-6632.2009.05275.x","volume":"1187","author":"V Yuferov","year":"2010","unstructured":"Yuferov V, Levran O, Proudnikov D, Nielsen DA, Kreek MJ . Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann NY Acad Sci 2010; 1187: 184\u2013207.","journal-title":"Ann NY Acad Sci"},{"key":"BFtpj201689_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.biopsych.2013.08.034","volume":"76","author":"J Gelernter","year":"2014","unstructured":"Gelernter J, Kranzler HR, Sherva R, Koesterer R, Almasy L, Zhao H et al. Genome-wide association study of opioid dependence: multiple associations mapped to calcium and potassium pathways. Biol Psychiatry 2014; 76: 66\u201374.","journal-title":"Biol Psychiatry"},{"key":"BFtpj201689_CR5","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s00210-002-0533-2","volume":"365","author":"A Becker","year":"2002","unstructured":"Becker A, Grecksch G, Kraus J, Loh HH, Schroeder H, Hollt V . Rewarding effects of ethanol and cocaine in mu opioid receptor-deficient mice. Naunyn Schmiedebergs Arch Pharmacol 2002; 365: 296\u2013302.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"BFtpj201689_CR6","first-page":"123","volume":"121","author":"FS Hall","year":"2004","unstructured":"Hall FS, Goeb M, Li XF, Sora I, Uhl GR . mu-Opioid receptor knockout mice display reduced cocaine conditioned place preference but enhanced sensitization of cocaine-induced locomotion. Brain Res 2004; 121: 123\u2013130.","journal-title":"Brain Res"},{"key":"BFtpj201689_CR7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.neuroscience.2006.06.013","volume":"142","author":"M Hummel","year":"2006","unstructured":"Hummel M, Schroeder J, Liu-Chen LY, Cowan A, Unterwald EM . An antisense oligodeoxynucleotide to the mu opioid receptor attenuates cocaine-induced behavioral sensitization and reward in mice. Neuroscience 2006; 142: 481\u2013491.","journal-title":"Neuroscience"},{"key":"BFtpj201689_CR8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/383819a0","volume":"383","author":"HW Matthes","year":"1996","unstructured":"Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996; 383: 819\u2013823.","journal-title":"Nature"},{"key":"BFtpj201689_CR9","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1073\/pnas.94.4.1544","volume":"94","author":"I Sora","year":"1997","unstructured":"Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM et al. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 1997; 94: 1544\u20131549.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFtpj201689_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/ng0594-54","volume":"7","author":"WH Berrettini","year":"1994","unstructured":"Berrettini WH, Ferraro TN, Alexander RC, Buchberg AM, Vogel WH . Quantitative trait loci mapping of three loci controlling morphine preference using inbred mouse strains. Nat Genet 1994; 7: 54\u201358.","journal-title":"Nat Genet"},{"key":"BFtpj201689_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.neuroscience.2014.07.020","volume":"277","author":"GA Doyle","year":"2014","unstructured":"Doyle GA, Schwebel CL, Ruiz SE, Chou AD, Lai AT, Wang MJ et al. Analysis of candidate genes for morphine preference quantitative trait locus Mop2. Neuroscience 2014; 277: 403\u2013416.","journal-title":"Neuroscience"},{"key":"BFtpj201689_CR12","first-page":"CD002207","volume":"2","author":"RP Mattick","year":"2014","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M . Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; 2: CD002207.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1 Suppl B","key":"BFtpj201689_CR13","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.18553\/jmcp.2010.16.S1-B.14","volume":"16","author":"L Nicholls","year":"2010","unstructured":"Nicholls L, Bragaw L, Ruetsch C . Opioid dependence treatment and guidelines. J Manag Care Pharm 2010; 16 (1 Suppl B): S14\u2013S21.","journal-title":"J Manag Care Pharm"},{"key":"BFtpj201689_CR14","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1001\/jama.286.14.1724","volume":"286","author":"DA Fiellin","year":"2001","unstructured":"Fiellin DA, O'Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS . Methadone maintenance in primary care: a randomized controlled trial. JAMA 2001; 286: 1724\u20131731.","journal-title":"JAMA"},{"key":"BFtpj201689_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0376-8716(00)80006-X","volume":"60","author":"PP Pani","year":"2000","unstructured":"Pani PP, Maremmani I, Pirastu R, Tagliamonte A, Gessa GL . Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend 2000; 60: 39\u201350.","journal-title":"Drug Alcohol Depend"},{"key":"BFtpj201689_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1001\/archpsyc.65.2.135","volume":"65","author":"RF Anton","year":"2008","unstructured":"Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 2008; 65: 135\u2013144.","journal-title":"Arch Gen Psychiatry"},{"key":"BFtpj201689_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1369-1600.2012.00442.x","volume":"17","author":"AJ Chamorro","year":"2012","unstructured":"Chamorro AJ, Marcos M, Miron-Canelo JA, Pastor I, Gonzalez-Sarmiento R, Laso FJ . Association of micro-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. Addict Biol 2012; 17: 505\u2013512.","journal-title":"Addict Biol"},{"key":"BFtpj201689_CR18","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/sj.tpj.6500238","volume":"4","author":"C Lerman","year":"2004","unstructured":"Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S et al. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 2004; 4: 184\u2013192.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201689_CR19","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1038\/sj.npp.1300219","volume":"28","author":"DW Oslin","year":"2003","unstructured":"Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003; 28: 1546\u20131552.","journal-title":"Neuropsychopharmacology"},{"key":"BFtpj201689_CR20","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/tpj.2013.30","volume":"14","author":"TK Clarke","year":"2014","unstructured":"Clarke TK, Crist RC, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ et al. Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. Pharmacogenomics J 2014; 14: 303\u2013308.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201689_CR21","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1038\/npp.2013.99","volume":"38","author":"RC Crist","year":"2013","unstructured":"Crist RC, Clarke TK, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ et al. An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology 2013; 38: 2003\u20132010.","journal-title":"Neuropsychopharmacology"},{"key":"BFtpj201689_CR22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1176\/appi.ajp.2013.13081014","volume":"171","author":"HR Kranzler","year":"2014","unstructured":"Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry 2014; 171: 445\u2013452.","journal-title":"Am J Psychiatry"},{"key":"BFtpj201689_CR23","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/tpj.2010.37","volume":"11","author":"B Oneda","year":"2011","unstructured":"Oneda B, Crettol S, Bochud M, Besson J, Croquette-Krokar M, Hammig R et al. beta-Arrestin2 influences the response to methadone in opioid-dependent patients. Pharmacogenomics J 2011; 11: 258\u2013266.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201689_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.gene.2005.05.040","volume":"364","author":"S Ide","year":"2005","unstructured":"Ide S, Han W, Kasai S, Hata H, Sora I, Ikeda K . Characterization of the 3' untranslated region of the human mu-opioid receptor (MOR-1) mRNA. Gene 2005; 364: 139\u2013145.","journal-title":"Gene"},{"key":"BFtpj201689_CR25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/jnr.21473","volume":"86","author":"F Bolognani","year":"2008","unstructured":"Bolognani F, Perrone-Bizzozero NI . RNA-protein interactions and control of mRNA stability in neurons. J Neurosci Res 2008; 86: 481\u2013489.","journal-title":"J Neurosci Res"},{"key":"BFtpj201689_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.yfrne.2009.08.001","volume":"31","author":"E Vreugdenhil","year":"2010","unstructured":"Vreugdenhil E, Berezikov E . Fine-tuning the brain: MicroRNAs. Front Neuroendocrinol 2010; 31: 128\u2013133.","journal-title":"Front Neuroendocrinol"},{"key":"BFtpj201689_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1673-8527(09)60001-1","volume":"36","author":"R Zhang","year":"2009","unstructured":"Zhang R, Su B . Small but influential: the role of microRNAs on gene regulatory network and 3'UTR evolution. J Genet Genomics 2009; 36: 1\u20136.","journal-title":"J Genet Genomics"},{"key":"BFtpj201689_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.drugalcdep.2012.08.002","volume":"128","author":"AJ Saxon","year":"2013","unstructured":"Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A et al. Buprenorphine\/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend 2013; 128: 71\u201376.","journal-title":"Drug Alcohol Depend"},{"key":"BFtpj201689_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","volume":"21","author":"JC Barrett","year":"2005","unstructured":"Barrett JC, Fry B, Maller J, Daly MJ . Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263\u2013265.","journal-title":"Bioinformatics"},{"key":"BFtpj201689_CR30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drugalcdep.2012.06.023","volume":"127","author":"RC Crist","year":"2013","unstructured":"Crist RC, Ambrose-Lanci LM, Vaswani M, Clarke TK, Zeng A, Yuan C et al. Case-control association analysis of polymorphisms in the delta-opioid receptor, OPRD1, with cocaine and opioid addicted populations. Drug Alcohol Depend 2013; 127: 122\u2013128.","journal-title":"Drug Alcohol Depend"},{"key":"BFtpj201689_CR31","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1086\/519795","volume":"81","author":"S Purcell","year":"2007","unstructured":"Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559\u2013575.","journal-title":"Am J Hum Genet"},{"key":"BFtpj201689_CR32","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0166-4328(01)00297-2","volume":"125","author":"Y Benjamini","year":"2001","unstructured":"Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I . Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001; 125: 279\u2013284.","journal-title":"Behav Brain Res"},{"key":"BFtpj201689_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","volume":"73","author":"K-Y Liang","year":"1986","unstructured":"Liang K-Y, Zeger S.L . Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13\u201322.","journal-title":"Biometrika"},{"key":"BFtpj201689_CR34","doi-asserted-by":"publisher","first-page":"605","DOI":"10.15288\/jsad.2013.74.605","volume":"74","author":"JS Potter","year":"2013","unstructured":"Potter JS, Marino EN, Hillhouse MP, Nielsen S, Wiest K, Canamar CP et al. Buprenorphine\/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). J Stud Alcohol Drugs 2013; 74: 605\u2013613.","journal-title":"J Stud Alcohol Drugs"},{"key":"BFtpj201689_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.addbeh.2010.08.008","volume":"36","author":"FL Shand","year":"2011","unstructured":"Shand FL, Degenhardt L, Slade T, Nelson EC . Sex differences amongst dependent heroin users: histories, clinical characteristics and predictors of other substance dependence. Addict Behav 2011; 36: 27\u201336.","journal-title":"Addict Behav"},{"key":"BFtpj201689_CR36","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/mp.2015.102","volume":"21","author":"EC Nelson","year":"2016","unstructured":"Nelson EC, Agrawal A, Heath AC, Bogdan R, Sherva R, Zhang B et al. Evidence of CNIH3 involvement in opioid dependence. Mol Psychiatry 2016; 21: 608\u2013614.","journal-title":"Mol Psychiatry"},{"key":"BFtpj201689_CR37","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1371\/journal.pgen.0020190","volume":"2","author":"N Patterson","year":"2006","unstructured":"Patterson N, Price AL, Reich D . Population structure and eigenanalysis. PLoS Genet 2006; 2: e190.","journal-title":"PLoS Genet"},{"key":"BFtpj201689_CR38","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1101\/gr.140269.112","volume":"23","author":"J Meunier","year":"2013","unstructured":"Meunier J, Lemoine F, Soumillon M, Liechti A, Weier M, Guschanski K et al. Birth and expression evolution of mammalian microRNA genes. Genome Res 2013; 23: 34\u201345.","journal-title":"Genome Res"},{"key":"BFtpj201689_CR39","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1124\/mol.113.089292","volume":"85","author":"Z Lu","year":"2014","unstructured":"Lu Z, Xu J, Xu M, Pasternak GW, Pan YX . Morphine regulates expression of mu-opioid receptor MOR-1A, an intron-retention carboxyl terminal splice variant of the mu-opioid receptor (OPRM1) gene via miR-103\/miR-107. Mol Pharmacol 2014; 85: 368\u2013380.","journal-title":"Mol Pharmacol"},{"key":"BFtpj201689_CR40","doi-asserted-by":"publisher","first-page":"21994","DOI":"10.1074\/jbc.M110.112607","volume":"285","author":"H Zheng","year":"2010","unstructured":"Zheng H, Chu J, Zeng Y, Loh HH, Law PY . Yin Yang 1 phosphorylation contributes to the differential effects of mu-opioid receptor agonists on microRNA-190 expression. J Biol Chem 2010; 285: 21994\u201322002.","journal-title":"J Biol Chem"},{"key":"BFtpj201689_CR41","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/BF02246290","volume":"119","author":"SL Walsh","year":"1995","unstructured":"Walsh SL, June HL, Schuh KJ, Preston KL, Bigelow GE, Stitzer ML . Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology 1995; 119: 268\u2013276.","journal-title":"Psychopharmacology"},{"key":"BFtpj201689_CR42","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/add.12834","volume":"110","author":"L Burns","year":"2015","unstructured":"Burns L, Gisev N, Larney S, Dobbins T, Gibson A, Kimber J et al. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia. Addiction 2015; 110: 646\u2013655.","journal-title":"Addiction"},{"key":"BFtpj201689_CR43","first-page":"309","volume-title":"Statistical and Methodological Myths and Urban Legends: Doctrine, Verity and Fable in the Organizational and Social Sciences","author":"D Chan","year":"2009","unstructured":"Chan D. So why ask me? Are self-report data really that bad? In: Lance CE, Vandenberg R.J. (ed). Statistical and Methodological Myths and Urban Legends: Doctrine, Verity and Fable in the Organizational and Social Sciences. Taylor & Franci: New York, USA, 2009, pp 309\u2013336."}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/tpj201689.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/tpj201689","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/tpj.2016.89","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/tpj201689.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:47:48Z","timestamp":1684622868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,13]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["BFtpj201689"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2016.89","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,13]]},"assertion":[{"value":"25 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Degenhardt has received educational grants from Mundipharma International and Indivior Dr Saxon receives funding from MedicaSafe and has received compensation from UpToDate, Indivior and Alkermes. Dr Ling is a consultant for Indivior, US WorldMed and Cerecor and also has research support from the Patient-Centered Outcomes Research Institute, Indivior, Alkermes and Brauburn Pharmaceuticals. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}